
Opinion|Videos|September 13, 2024
Cost Considerations With Intravenous and Subcutaneous Biologics
Author(s)Jennifer Seminerio, MD
Key topics in cost of intravenous and subcutaneous biologics are discussed by Dr Seminerio.
Advertisement
Episodes in this series

Video content above is prompted by the following:
- How do you evaluate the costs between IV vs. subQ therapies when deciding which route of administration to use in patients?
Advertisement
Related to this article

National Alliance names Jenny Goins interim CEO after former leader’s arrest; details emerge on charges, firing timeline, and impact on healthcare policy circles.

Only 19% use AI predictive models in cancer care despite strong belief in impact; 2026 Oncology Care Index highlights reimbursement, training, funding barriers.

Hispanic HIV incidence rose 16.8% in antisanctuary counties after the 2018 public charge announcement, relative to baseline counties, a new study found.

A review of randomized clinical trials, nonrandomized trials and case reports suggests that the inflammatory bowel disease risk from treatment with IL-17 inhibitors is low.

From a 95% remission rate in Japan to $81.6 billion in U.S. savings since 2015 — a data-driven look at where biosimilars stand today, and where the gaps remain.

AI pathology tool measures lung cancer treatment response after neoadjuvant chemoimmunotherapy with 91% accuracy, speeding NSCLC care while needing review for complete response.

A review of 57 studies found music eases pain through positive emotion, control and moving in time with the beat, according to recent research out of Drexel University.
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
National Alliance names interim head after arrest of its president
2
The quest to keep skin from aging may lead here
3
The IBD risk among patients with hidrandentitis suppurtiva treated with IL-17 inhibitors: Low but not nothing
4
Why people under 50 may develop fatty liver disease
5





